GB0710522D0 - Drug delivery system comprising matrix metalloproteinase inhibitors - Google Patents

Drug delivery system comprising matrix metalloproteinase inhibitors

Info

Publication number
GB0710522D0
GB0710522D0 GBGB0710522.4A GB0710522A GB0710522D0 GB 0710522 D0 GB0710522 D0 GB 0710522D0 GB 0710522 A GB0710522 A GB 0710522A GB 0710522 D0 GB0710522 D0 GB 0710522D0
Authority
GB
United Kingdom
Prior art keywords
delivery system
drug delivery
matrix metalloproteinase
metalloproteinase inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0710522.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Veterinary College
Original Assignee
Royal Veterinary College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Veterinary College filed Critical Royal Veterinary College
Priority to GBGB0710522.4A priority Critical patent/GB0710522D0/en
Publication of GB0710522D0 publication Critical patent/GB0710522D0/en
Priority to PCT/GB2008/001865 priority patent/WO2008146018A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
GBGB0710522.4A 2007-06-01 2007-06-01 Drug delivery system comprising matrix metalloproteinase inhibitors Ceased GB0710522D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0710522.4A GB0710522D0 (en) 2007-06-01 2007-06-01 Drug delivery system comprising matrix metalloproteinase inhibitors
PCT/GB2008/001865 WO2008146018A2 (en) 2007-06-01 2008-05-30 Drug delivery system comprising matrix metalloproteinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0710522.4A GB0710522D0 (en) 2007-06-01 2007-06-01 Drug delivery system comprising matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
GB0710522D0 true GB0710522D0 (en) 2007-07-11

Family

ID=38289709

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0710522.4A Ceased GB0710522D0 (en) 2007-06-01 2007-06-01 Drug delivery system comprising matrix metalloproteinase inhibitors

Country Status (2)

Country Link
GB (1) GB0710522D0 (en)
WO (1) WO2008146018A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2012112919A1 (en) * 2011-02-17 2012-08-23 Rhode Island Hostpital Stromal derived factor inhibition and cxcr4 blockade
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP2852383A4 (en) * 2012-05-21 2016-03-16 Dcb Usa Llc Methods for drug screen using zebrafish model and the compounds screened thereform
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EA035336B1 (en) 2013-12-09 2020-05-29 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити Method for treating aging-associated cognitive disorder or disease
EA201890020A1 (en) 2015-06-15 2018-05-31 Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити METHODS AND COMPOSITIONS FOR THE TREATMENT OF ASSOCIATED WITH AGING STATES
CN105079799A (en) * 2015-07-27 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 Application of matrix metallo-proteinase inhibitor in resisting nuclear radiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
DE10304994A1 (en) * 2003-02-07 2004-09-02 Aventis Pharma Deutschland Gmbh The use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis
US20070259030A1 (en) * 2006-05-05 2007-11-08 Drapeau Susan J Methods, systems and reagents for tendon and ligament therapy

Also Published As

Publication number Publication date
WO2008146018A2 (en) 2008-12-04
WO2008146018A3 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
ZA201002014B (en) Drug delivery system
GB2442875B (en) Regulated drug delivery system
GB0710522D0 (en) Drug delivery system comprising matrix metalloproteinase inhibitors
ZA201101737B (en) Progestin-containing drug delivery system
EP2178598A4 (en) Iontophoretic drug delivery system
HK1144375A1 (en) Transdermal delivery system
IL224505A (en) Device for drug delivery
IL200077A0 (en) Transdermal delivery systems
HK1179189A1 (en) Devices for fluid drug delivery
IL242028A0 (en) Micropump-operated drug dosing system
IL219001A0 (en) Drug delivery device
IL198911A0 (en) Drug delivery
ZA200807006B (en) Drug delivery device
IL183295A0 (en) Drug delivery device
EP2132133A4 (en) Particulate drug delivery
EP2007358A4 (en) Swellable particles for drug delivery
DK2185220T3 (en) Device for drug delivery
EP2299989A4 (en) Stabilized transdermal drug delivery system
EP1901796A4 (en) Drug delivery system
HK1202083A1 (en) Iontophoretic drug delivery system
IL212357A0 (en) Sustained drug delivery system
ZA201103240B (en) Sustained release drug delivery system
ZA200903317B (en) Helically-shaped drug delivery system
GB0606415D0 (en) Topical drug delivery
EP2226083A4 (en) Drug delivery system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)